Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | NR2E1 | Q9Y466 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.59 |
| ▸ | BRAF | P15056 | 4/20 | 0.57 |
| ▸ | RAF1 | P04049 | 4/20 | 0.57 |
| ▸ | LDLR | P01130 | 1/20 | 0.56 |
| ▸ | KIT | P10721 | 1/20 | 0.56 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.56 |
| ▸ | ABL1 | P00519 | 7/20 | 0.56 |
| ▸ | BCR | P11274 | 4/20 | 0.56 |
| ▸ | SRC | P12931 | 3/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.56 |
| ▸ | FYN | P06241 | 1/20 | 0.56 |
| ▸ | YES1 | P07947 | 1/20 | 0.56 |
| ▸ | LYN | P07948 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15381989 | 0.89 | CSF1R (0.71) | CSF1RKDM4EPOLBRECQLNR2E1 | |
| SCHEMBL24071010 | 0.89 | NR2E1 (0.71) | NR2E1LDLRKITPCSK9ABL1 | |
| SCHEMBL30211941 | 0.89 | NR2E1 (0.71) | NR2E1LDLRKITPCSK9ABL1 | |
| SCHEMBL4252903 | 0.87 | CSF1R (0.66) | CSF1RKDM4EPOLBRECQLNR2E1 | |
| SCHEMBL21612152 | 0.87 | CSF1R (0.71) | CSF1RKDM4EPOLBRECQLNR2E1 | |
| SCHEMBL4252904 | 0.87 | CSF1R (0.68) | CSF1RKDM4EPOLBRECQLNR2E1 | |
| SCHEMBL15382274 | 0.85 | CSF1R (0.49) | CSF1RKDM4EPOLBRECQLNR2E1 | |
| SCHEMBL15381988 | 0.85 | CSF1R (0.66) | CSF1RKDM4EPOLBRECQLNR2E1 | |
| SCHEMBL17208743 | 0.84 | CSF1R (0.57) | CSF1RKDM4EPOLBRECQLNR2E1 | |
| SCHEMBL3720917 | 0.84 | CSF1R (0.65) | CSF1RKDM4EPOLBRECQLNR2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2396325-B1 | DERIVATIVES OF AZAINDOLES AS INHIBITORS OF PROTEIN KINASES ABL AND SRC | ORIBASE PHARMA (FR) | 2015-04-01 | — | — | EP | disclosed |
| EP-2396325-B1 | DERIVATIVES OF AZAINDOLES AS INHIBITORS OF PROTEIN KINASES ABL AND SRC | ORIBASE PHARMA (FR) | 2015-04-01 | — | — | EP | disclosed |
| US-8580815-B2 | Derivatives of azaindoles as inhibitors of protein kinases ABL and SRC | ORIBASE PHARMA (FR) | 2013-11-12 | — | — | US | disclosed |
| US-8580815-B2 | Derivatives of azaindoles as inhibitors of protein kinases ABL and SRC | ORIBASE PHARMA (FR) | 2013-11-12 | — | — | US | disclosed |
| US-20110312959-A1 | Derivatives of Azaindoles as Inhibitors of Protein Kinases ABL and SRC | ORIBASE PHARMA (FR) | 2011-12-22 | — | — | US | disclosed |
| US-20110312959-A1 | Derivatives of Azaindoles as Inhibitors of Protein Kinases ABL and SRC | ORIBASE PHARMA (FR) | 2011-12-22 | — | — | US | disclosed |
| EP-2396325-A1 | DERIVATIVES OF AZAINDOLES AS INHIBITORS OF PROTEIN KINASES ABL AND SRC | OriBase Pharma (FR) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010092489-A1 | DERIVATIVES OF AZAINDOLES AS INHIBITORS OF PROTEIN KINASES ABL AND SRC | NOVA DECISION (FR) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010092489-A1 | DERIVATIVES OF AZAINDOLES AS INHIBITORS OF PROTEIN KINASES ABL AND SRC | NOVA DECISION (FR) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312959-A1 | Derivatives of Azaindoles as Inhibitors of Protein Kinases ABL and SRC | ABL1, ABL2, SRC | CSF1R 2338/4885KDM4E 2066/4885POLB 3084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.